Old Web
English
Sign In
Acemap
>
authorDetail
>
Helgi van de Velde
Helgi van de Velde
Janssen Pharmaceutica
Immunology
Medicine
Neutropenia
Discontinuation
Siltuximab
3
Papers
31
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease
2013
Blood
Frits van Rhee
Corey Casper
Peter M. Voorhees
Luis E Fayad
Helgi van de Velde
Jessica Vermeulen
Xiang Qin
Ming Qi
Brenda J. Tromp
Razelle Kurzrock
Show All
Source
Cite
Save
Citations (8)
Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study
2013
Blood
Maria-Victoria Mateos
Paul G. Richardson
Hongliang Shi
Liviu Niculescu
Jennifer Elliott
Edward Dow
Helgi van de Velde
Jesús F. San-Miguel
Show All
Source
Cite
Save
Citations (10)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease
2013
Blood
Raymond S. M. Wong
Corey Casper
Nikhil C. Munshi
Xiaoyan Ke
Alexander Fossa
David M. Simpson
Marcelo Capra
Ting Liu
Ruey-Kuen Hsieh
Yeow-Tee Goh
Jun Zhu
Seok-Goo Cho
Hanyun Ren
James Cavet
Rajesh Bandekar
Margaret Rothman
Thomas A. Puchalski
Shalini Chaturvedi
Helgi van de Velde
Jessica Vermeulen
Frits van Rhee
Show All
Source
Cite
Save
Citations (13)
1